Through a process of drug screening focusing on Ras/MAPK and PI3K/Akt/mTOR signal transduction pathways using canine mucosal melanoma cell lines and preclinical xenograft models, small molecule kinase inhibitors sapanisertib and trametinib were chosen for further evaluation as a combination (13). This evidence concerns the gene MTOR and melanoma.